Company: VCYT
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001384101-25-000110
Chunk: 120

Company: VERACYTE, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 2
Chunk 120
---
 and six months ended June 30, 2025 and 2024 (in thousands of dollars, except percentages and test volume):

 Three Months Ended June 30,Six Months Ended June 30, 20252024Change%20252024Change%Revenue:        Testing revenue$122,263 $106,970 $15,293 14%$229,572 $197,273 $32,299 16%Product revenue3,598 3,906 (308)(8)%7,178 7,443 (265)(4)%Biopharmaceutical and other revenue4,303 3,552 751 21%7,887 6,556 1,331 20%Total revenue130,164 114,428 15,736 14%244,637 211,272 33,365 16%Cost of revenue:    Cost of testing revenue32,407 27,920 4,487 16%60,667 53,899 6,768 13%Cost of product revenue1,749 1,874 (125)(7)%3,171 4,518 (1,347)(30)%Cost of biopharmaceutical and other revenue3,572 3,812 (240)(6)%6,270 6,650 (380)(6)%Intangible asset amortization - cost of revenue2,667 2,909 (242)(8)%5,252 5,824 (572)(10)%Total cost of revenue40,395 36,515 3,880 11%75,360 70,891 4,469 6%Gross profit89,769 77,913 11,856 15%169,277 140,381 28,896 21%Operating expenses:Research and development16,264 16,465 (201)(1)%33,984 32,430 1,554 5%Selling and marketing25,316 24,216 1,100 5%49,770 47,998 1,772 4%General and administrative32,331 31,745 586 2%66,139 57,955 8,184 14%Impairment of assets20,505 — 20,505 NM20,505 429 20,076 4680%Intangible asset